Shanghai Zhangjiang Biotechnology Limited Company Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Pudong United States (1996)
Status: Left NME R&D (1996)

Organization Overview

First Clinical Trial
2009
NCT01550055
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Asthma (Phase 3)

Carcinoma in Situ (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Cervical Intraepithelial Neoplasia (Phase 2)

Collagen Diseases (Phase 1)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 2)

Hemangioma, Capillary (Phase 4)

Infections (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 1)

Papillomavirus Infections (Phase 2)

Port-Wine Stain (Phase 4)

Rheumatic Diseases (Phase 1)

Squamous Intraepithelial Lesions of the Cervix (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 15